Cephradine
A first-generation cephalosporin available in both oral and parenteral formulations, used for mild to moderate respiratory, skin, and urinary tract infections caused by gram-positive and some gram-negative bacteria. It was notable for being one of the few early cephalosporins available in both formulation types. Its clinical use has largely declined in favor of more modern antibiotics.
الوزن الجزيئي
349,4000 g/mol
LogP
0,40
TPSA
138,00 Ų
قاعدة ليبينسكي للخمسة
ناجح
آلية العمل
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1
InChI
InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
Molecular Formula
C16H19N3O4S
HBD / HBA
3 / 6
الروابط القابلة للدوران
4
الذرات الثقيلة
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
A first-generation cephalosporin available in both oral and parenteral formulations, used for mild to moderate respiratory, skin, and urinary tract infections caused by gram-positive and some gram-negative bacteria. It was notable for being one of the few early cephalosporins available in both formulation types. Its clinical use has largely declined in favor of more modern antibiotics.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cephradine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1604. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 38103. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cephradine"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cephradine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cephradine/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cephradine/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cephradine"></drugfyi-drug>